Category Archives: Uncategorized

CDC Pink Book Webinars


Pink Book Webinar Series

Epidemiology and Prevention of Vaccine-Preventable Diseases Pink Book cover

This online series of 15 webinars provides an overview of the principles of vaccination, general recommendations, immunization strategies for providers, and specific information about vaccine-preventable diseases and the vaccines that prevent them. Each one-hour webinar explores a chapter from the 13th edition of “Epidemiology and Prevention of Vaccine-Preventable Diseases,” also known widely as “The Pink Book.”

2019 Pink Book Webinar Registration


Immunization providers: Physicians, nurses, nurse practitioners, pharmacists, physician assistants, DoD paraprofessionals, medical students, state and local immunization programs, etc.

Continuing Education

Continuing education will be available for each event.

2019 Webinar Schedule & Archives

(All events begin at noon eastern time.)

2018 webinar schedule with presentation information
Date Topic
June 5 Principles of Vaccination
June 12 General Best Practice Guidelines, Part 1
June 19 General Best Practice Guidelines, Part 2, and Vaccine Safety
July 10 Immunization Strategies
July 17 Vaccine Storage and Handling and Vaccine Administration
July 24 DTaP/Tdap
July 31 Rotavirus and Hepatitis A
August 7 Meningococcal Vaccines
August 14 Measles, Mumps, Rubella
August 21 Polio and Hib
August 28 Varicella and Zoster
September 4 Hepatitis B
September 11 HPV
September 18 Pneumococcal Vaccines
September 25 Influenza


St. Margaret Bloomfield Garfield Family Health Center Recognized

2019 HPV Vaccine is Cancer Prevention Award Winner Spotlights


University of Pittsburgh Medical Center— St. Margaret Bloomfield Garfield Family Health Center

University of Pittsburgh Medical Center— St. Margaret Bloomfield Garfield Family Health Center
Pittsburgh, PA

The University of Pittsburgh Medical Center (UPMC) St. Margaret Bloomfield Garfield Family Health Center was established in 1984, in a disadvantaged urban neighborhood in Pittsburgh, Pennsylvania. The health center serves predominantly low income and African American patients, registering 10,000 patient visits per year. It also serves as headquarters for the school health partnership with five East End Pittsburgh schools.

Over the past few years, the health center pursued two successive quality improvement projects to increase HPV vaccination rates for their patients. These projects have been successful due to strong leadership and enthusiastic participation of the entire staff. Serving as the health center’s vaccine champion, Dr. Donald Middleton teaches residents and faculty to make an effective recommendation using presumptive language. In addition to being a champion for the health center, Dr. Middleton also shares his expertise on how to make effective vaccine recommendations at local, UPMC system, county, regional, and national meetings.

Staff at the health center take prevention seriously, while addressing it in fun, engaging ways. Creativity and perseverance are the hallmarks of their HPV vaccination improvement project. One of the health center’s pharmacists interviewed students at a local high school; the students recommended posters containing facts about HPV consequences, an immediate reward for vaccine receipt, and text messaged vaccination reminders. The health center also sponsors an HPV poster contest in the local community; the winning posters are included in their fifth-grade puberty classes and educational materials.

These efforts led the health center to an impressive 77% completion rate for both male and female patients. For their innovative approach to improving vaccination rates in their community, the UPMC St. Margaret Bloomfield Garfield Family Health Center is Pennsylvania’s 2019 HPV Vaccine Is Cancer Prevention Champion!

More information on the winners from the other states can be found at:

Vaccine App from the Vaccine Education Center at CHOP

Free Mobile App – Vaccines on the Go: What You Should Know

It’s easier than ever to get health information. But sometimes, it’s difficult to weed out the “good” information, which is scientifically accurate, from the “bad” information, which is not based on science. This is especially true for vaccines.

In a continued effort to provide the public with information about the science, safety and importance of vaccines, the Vaccine Education Center at Children’s Hospital of Philadelphia (VEC) recently updated its popular app, called Vaccines on the Go: What You Should Know, so anyone can access vaccine information wherever and whenever they need it.

Vaccine app features

The redesigned Vaccines on the Go: What You Should Know mobile app continues to offer information about:

  • Vaccines and the diseases they prevent
  • Recommended immunization schedules for children, teens and adults
  • Vaccine safety concerns, including autism, thimerosal, and too many vaccines

New information includes:

  • How the immune system works, including what happens during an infection or when a person is immune compromised
  • Disease and vaccine information related to travel, including descriptions of cholera, Japanese encephalitis virus, typhoid and yellow fever
  • Enhanced video offerings, including animations related to how viruses attack cells, maternal antibodies and immunizations, and more

Additional features include:

  • Updated graphics depicting disease characteristics, such as levels of contagiousness and typical disease timelines
  • An opportunity to receive updates through the app
  • Vaccine-related trivia
  • A place to record notes or questions for the next doctor’s visit
  • Ways to stay connected with the VEC, including sending us vaccine-related questions or signing up for Parents PACK, our free monthly e-newsletter
  • Links to a variety of online resources, including booklets and Q&A sheets

Providers: Get free posters to share with your patients

If you would like to share information about this app with your patients and their families, you can order free updated posters from the VEC. Posters are 8.5”x11” in size, making them easy to hang in waiting or exam rooms or to add to patient information packets.

App wins “Award of Distinction”

VEC Communicator Award Badge In 2014, the Vaccines on the Go mobile App was selected among 6,000 entries as an “Award of Distinction” winner in the annual Academy of Interactive and Visual Arts’ Communicator Awards.

Reviewed on October 23, 2019

Dengue Vaccine Update

Takeda’s tetravalent dengue vaccine candidate effective in children

Photo of Derek Wallace

Derek Wallace

Results of an ongoing phase 3 trial of Takeda’s tetravalent dengue vaccine candidate, known as TAK-003, suggest that the vaccine is effective in children and adolescents aged 4 to 16 years.

The findings, which were presented previously at the annual meeting of the American Society of Tropical Medicine and Hygiene, have now been published in The New England Journal of Medicine.

“It is important that there are multiple options to fight dengue, as it is the fastest spreading mosquito-borne disease and one of the top 10 threats to global health, according to WHO,” Derek Wallace, MBBS, vice president and global program lead in dengue for Takeda, told Infectious Diseases in Children. “In the absences of a specific treatment, prevention of dengue becomes very important.”

Wallace stressed that vector control and personal measures to reduce exposure to mosquitos have not been sufficient in preventing disease.

One other tetravalent dengue vaccine, known as Dengvaxia (CYD-TDV, Sanofi Pasteur), has been used in children in Asia and Latin America. However, Wallace and colleagues wrote that the vaccine increased the risk for severe dengue and dengue-related hospitalizations in children who had never been infected with the virus. Because of the increased risk for severe outcomes, Dengvaxia is only recommended for those with confirmed previous dengue virus infection.

“This leaves a significant unmet need for a vaccine that is safe and protects those at risk for dengue regardless of previous dengue exposure,” Wallace said.

For the trial, the researchers administered TAK-003 to healthy children and adolescents residing in endemic areas in Asia and Latin America. Participants received either two doses of the vaccine or placebo, with 3 months between each dose.

More than 20,000 children and adolescents were administered at least one dose of the vaccine or placebo, and nearly all (94.8%) received both doses. Wallace and colleagues wrote that one dose of the vaccine was 80.9% effective (95% CI, 75.2%-85.3%). Compared with placebo, the rate of infection was lower among children who received one dose of the vaccine (0.5 vs. 2.5 cases per 100 person-years).

Wallace said that the efficacy between the first and second dose of TAK-003 was “important and unexpected.”

“While this may have relevance for travelers and in outbreak settings, long-term safety and efficacy is assessed after two doses,” he said. “We therefore intend to file with a two dose regimen.”

Two doses of the vaccine were 80.2% (95% CI, 73.3%-85.3%) effective at preventing infection . The researchers identified fewer cases of virologically confirmed dengue virus infection among those who received two doses of the vaccine compared with placebo (61 vs. 149), and there was a 95.4% (95% CI, 88.4%-98.2%) reduction in hospitalizations due to dengue among recipients of TAK-003.

That last finding has “significant potential relevance,” according to Wallace.

“Dengue is an epidemic disease and creates huge pressure on public health infrastructure,” he explained. “There are an estimated 500,000 hospitalizations due to dengue each year. A reduction in hospitalization is therefore relevant both to the individual and to the public health systems in dengue-endemic areas. We are especially encouraged to note that the reduction in risk of hospitalization was observed in both seropositive and seronegative individuals.”

Before vaccination, 27.7% of participants who received both doses of TAK-003 were seronegative at baseline. Wallace and colleagues wrote that the vaccine demonstrated 74.9% efficacy in these children and adolescents (95% CI, 57%-85.4%), with 20 cases of virologically confirmed dengue virus infection occurring among those who received the vaccine and 39 cases among those who received placebo.

The researchers identified similar rates of adverse events among those who received the vaccine (3.1%) and those who received placebo (3.8%).

Wallace said the next steps in the trial include an analysis of an additional 6 months of data to determine the vaccine’s efficacy by serotype, baseline serostatus and severity of disease. He said these data will be presented at the upcoming American Society of Tropical Medicine and Hygiene annual meeting. A third analysis will examine the vaccine’s efficacy and long-term safety after an additional 3 years.

“We continue to collaborate with governments, nongovernmental organizations, policy organizations and dengue experts to ensure they have early and ongoing access to our data,” Wallace said. “These are the individuals and groups that are most important in defining how the vaccine candidate could potentially best be used. We will focus on filing in dengue-endemic countries where there is the greatest need in parallel with filings in nonendemic countries. The planned dossier will include safety and efficacy data from our trial and supporting data from our other phase 3 studies.” – by Katherine Bortz

Disclosures: Wallace is an employee of Takeda. Please see the study for all other authors’ relevant financial disclosures.

Contact your Representatives to Support the Vaccine Act


June 12, 2019

Urge Congress to Support the VACCINES Act

Please take two minutes to click here and encourage your US Representatives and Senators to cosponsor the bipartisan VACCINES Act, a bill to study, track, and address vaccine hesitancy and barriers to vaccination with federally supported evidence-based responses. VACCINES—the Vaccine Awareness Campaign to Champion Immunization Nationally and Enhance Safety Act—includes priorities identified by IDSA that will strengthen the U.S. public health system’s capacities to predict and prevent vaccine-preventable outbreaks and support health care providers with educational tools to discuss vaccination with families.

The House bill was introduced by Rep. Kim Schrier (D-WA) and is co-led by Rep. Michael Burgess (R-TX), Rep. Eliot Engel (D-NY), Rep. Kurt Schrader (D-OR), Rep. Gus Bilirakis (R-FL) and Rep. Brett Guthrie (R-KY). The Senate bill was introduced by Sen. Gary Peters (D-MI) with Sen. Pat Roberts (R-KS) and Sen. Tammy Duckworth (D-IL).



ACHD Issues School Immunization Report for 2017-18

The Allegheny County Health Department (ACHD) requires all schools (public, private/independent, parochial/religious, charter, and cyber) to submit the immunization status of their students annually to ensure that schools in Allegheny County are complying with state and county immunization regulations, .

This report, which summarizes the county’s immunization data for the 2017-18 school year, is organized into four parts: 1) overall immunization, 2) provisional enrollment, 3) immunization exemptions, and 4) immunization status by type of vaccine.

Data are primarily presented by school type or by grade. Also included are data from previous school years.


  • The percentage of students with all immunizations required for school entry was 96.3% in December 2017, which is above the Healthy People 2020 goal of 95% coverage.
  • The only grade that did not exceed 95% complete immunization coverage was 12th grade (92.9%), as this grade had new immunization requirements for students.
  • The majority of Allegheny County schools (78.0%) had at least 95% of their students fully immunized.
  • In Allegheny County, 0.7% of all students started school in the fall with provisional enrollment status; kindergarten (1.1%) and 12th grade (2.9%) had higher percentages of students enrolled provisionally due to new or additional immunization requirements.
  • Overall, 3.0% of students submitted medical or religious exemptions. Parochial/religious schools (4.6%) and private/independent schools (4.7%) had the highest percentage of exemptions.

View/Download the 2017-18 School Immunization Report here.

AAP releases immunization social media toolkit

The AAP Childhood Immunization Program has developed an Immunization Social Media Toolkit. This toolkit helps pediatric offices build support for immunizations in their own practices and answer common questions outside of the visit while using their role as trusted professionals to inform families about vaccines. The toolkit offers guidance for choosing a social media platform and setting up and managing an account.aaplogopos Pre-written tweets and posts with resources are also available for practices to copy and paste to make social media simpler.

Related Links